<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
December 7, 2000
----------------------------------
(Date of earliest event reported)
Cephalon, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-19119 23-2484489
--------------------------------- ------------ -------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) ID No.)
145 Brandywine Parkway
West Chester, Pennsylvania 19380
---------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
(610) 344-0200
------------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
-----------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
For the past several years, the Company has been cooperating with an
investigation conducted by the Office of Consumer Litigation of the U.S.
Department of Justice (the "Department"), relating to the release during the
period 1994-96 of some lots of MYOTROPHIN(R) (mecasermin) Injection used in
clinical trials and related reports filed with the U.S. Food and Drug
Administration.
On December 7, 2000, the Company learned that the Department had closed its
investigation and would not take any action against the Company or any of its
employees or former employees in connection with this matter. A copy of the
Department's letter to Company counsel is attached hereto as Exhibit 99.1, and
made a part of this Item 5.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CEPHALON, INC.
Date: December 8, 2000 By: /s/ FRANK BALDINO, JR.
------------------------
Frank Baldino, Jr.
Chairman and Chief Executive Officer
<PAGE>
EXHIBIT INDEX
Exhibit Page
------- ----
99.1 Letter from U.S. Department of Justice dated December 5, 2000.
